Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients

被引：0
|
作者：
Joseph, Nisha [1 ]
Kaufman, Jonathan [1 ]
Lonial, Sagar [1 ]
Hofmeister, Craig [1 ]
Dhodapkar, Madhav [1 ]
Gupta, Vikas [1 ]
DiCamillo, Sara [1 ]
Roberts, Danielle [1 ]
Boise, Lawrence [1 ]
Nooka, Ajay [1 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-141
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [41] Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Gupta, Vilas A.
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Boise, Lawrence H.
    DiCamillo, Sara M.
    Roberts, Danielle
    Nooka, Ajay K.
    Lonial, Sagar
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [42] Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN
    Silbermann, Rebecca
    Laubach, Jacob
    Kaufman, Jonathan L.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Costa, Luciano J.
    Anderson, Larry D.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Gries, Katharine S.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Voorhees, Peter M.
    Usmani, Saad Z.
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1257 - 1268
  • [43] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
    Sonneveld, Pieter
    Broijl, Annemiek
    Gay, Francesca
    Boccadoro, Mario
    Einsele, Hermann
    Blade, Joan
    Dimopoulos, Meletios A.
    Delforge, Michel
    Spencer, Andrew
    Hajek, Roman
    Schjesvold, Fredrik
    Lonergan, Sarah
    Smith, Elena
    Carson, Robin L.
    Crist, Wendy
    Garvin, Wendy S.
    Vermeulen, Jessica
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients
    Joseph, Nisha
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Dhodapkar, Madhav V.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2018, 132
  • [45] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Maclachlan, Kylee
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Usmani, Saad
    Lesokhin, Alexander
    Korde, Neha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
  • [46] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study
    Sborov, Douglas
    Baljevic, Muhamed
    Reeves, Brandi
    Laubach, Jacob
    Efebera, Yvonne
    Rodriguez, Cesar
    Costa, Luciano
    Chari, Ajai
    Silbermann, Rebecca
    Holstein, Sarah
    Anderson, Larry D., Jr.
    Kaufman, Jonathan
    Shah, Nina
    Pei, Huiling
    Patel, Sharmila
    Cortoos, Annelore
    Bartlett, Blake
    Vermeulen, Jessica
    Lin, Thomas
    Voorhees, Peter
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S135 - S136
  • [47] Outcomes of a bortezomib-based induction regimen (sequential or upfront triple association with lenalidomide) in transplant-eligible patients withh newly diagnosed multiple myeloma
    Paulos-Mesquita, Isabel
    Vieira, Joana
    Espada, Eduardo
    Martins-Almeida, Pedro
    Duarte, Margarida
    Lopes-Silva, Catarina
    Martins, Helena
    Raposo, Joao
    Esteves, Graca
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S121 - S121
  • [48] Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma
    Hungria, Vania T. M.
    Moura, Fernanda Lemos
    Soares, Paulo
    Lima, Juliana Souza
    Ricci, Lisa Aquaroni
    Nucci, Fabio Moore
    Oliveira Ribeiro, Eduardo Flavio
    Crusoe, Edvan de Queiroz
    Lima, Marinus de Moraes
    Pessoa de Magalhaes Filho, Roberto Jose
    Arrais-Rodrigues, Celso
    Bhaumik, Amitabha
    Parekh, Trilok
    Borgsten, Fredrik
    Carson, Robin
    Trufelli, Damila C.
    Costa, Abel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S230 - S230
  • [49] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Yvette N. Lamb
    Drugs, 2020, 80 : 1455 - 1464
  • [50] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Lamb, Yvette N.
    DRUGS, 2020, 80 (14) : 1455 - 1464
12345